Somapacitan - Novo Nordisk
Alternative Names: Albumin-binding somatropin - Novo Nordisk; Growth hormone derivative - Novo Nordisk; Long-acting growth hormone - Novo Nordisk; Long-acting somatropin -… See moreLatest Information Update: 25 Oct 2024
At a glance
- Originator Novo Nordisk
- Class Growth hormones; Hormonal replacements; Tetrazoles
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Somatotropin deficiency
Most Recent Events
- 26 Sep 2024 Novo Nordisk completes a phase II REAL 3 trial in Somatotropin deficiency (In children) in US, Austria, Brazil, France, Germany, India, Israel, Japan, Slovenia, Sweden, Turkey and Ukraine (SC) (NCT02616562)
- 01 Jun 2024 Efficacy data from the phase II REAL5 trial for Somatotropin deficiency presented at the Annual Meeting of the Endocrine Society (ENDO-2024),
- 18 Dec 2023 Novo Nordisk completes the phase III trial in Somatotropin deficiency (In children) in China (SC) (NCT04970654)